Regeneron says antibody cocktail is effective in preventing symptomatic COVID-19 infection

More On:

COVID vaccine

Norwegian Cruise Line making COVID-19 vaccine mandatory for crew

Moderna COVID-19 vaccine should not be used on pregnant women: WHO

Early results on Pfizer vaccine are encouraging, Israeli HMO says

Casino mogul, actress wife pose as motel workers to cut vaccine line

The antibody cocktail used to treat COVID-19 has shown to be 100 percent effective at protecting against symptomatic cases of the bug, according to new data released Tuesday.

Regeneron said its REGEN-COV treatment completely reduced symptomatic infections and cut overall rates of infections to about 50 percent in about 400 participants who was living with a COVID-19 patient.

Ten out of 186 people who received the treatment contracted COVID-19 but did not experience symptoms.

Those participants also had smaller viral loads and a shorter period of viral shedding, the company said.

The Westchester-based biotechnology giant said the treatment could be used as a “passive vaccine” following the Phase 3 results in the trial jointly run by the National Institute of Allergy and Infectious Diseases.

In November, the Food and Drug Administration greenlit Regeneron’s therapy for mild to moderate COVID-19 cases in adults and children.

A “passive vaccine” involves delivering virus-fighting antibodies into the body — unlike traditional vaccines which activates a person’s immune system to develop their own antibodies.

Full results from the trial are expected in the second quarter.

Share this article:

Source: Read Full Article